OncRef

Clinical Trial: NCT01356680

HD17 for Intermediate Stage Hodgkin Lymphoma

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:University of Cologne
Information Provided By:University of Cologne
Last Update Posted:2020-04-06

Study Overview

Brief Summary

This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS).

Official Title

HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma

Conditions

Hodgkin Lymphoma

Intervention / Treatment

  • Drug: BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)
  • Drug: ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)
  • Radiation: 30Gy IF-RT (Involved-Field Radiotherapy)
  • Radiation: 30Gy IN-RT (Involved-Node Radiotherapy)

Other Study ID Numbers

  • HD17

Start Date (Actual)

2012-01-13

Primary Completion Date (Actual)

2020-03-21

Study Completion Date (Actual)

2020-03-23

Enrollment (Actual)

1100

Study Type

Interventional

Phase

Phase 3